Morbidity, Clinical Course and Vaccination against SARS-CoV-2 Virus in Patients with Duchenne Muscular Dystrophy: A Patient Reported Survey

Int J Environ Res Public Health. 2021 Dec 30;19(1):406. doi: 10.3390/ijerph19010406.

Abstract

Background: Patients with Duchenne muscular dystrophy (DMD) may be at higher risk of a severe course of COVID-19. The aim of the study was to evaluate: (1) the incidence and course of COVID-19 infection in DMD patients; (2) the vaccination status of DMD patients; and (3) COVID-19 related anxiety among DMD families. Materials and Methods: The study was conducted during an online symposium for DMD patients and their families. All participants (DMD families; n = 150) were asked to fill in the online survey with questions about COVID-19 infection history, vaccination against SARS-CoV-2 and anxiety during pandemic. Results: 53 DMD patients filled in the survey. Five (9.43%) were COVID-19 positive with mild symptoms of respiratory infection and anosmia; 23 (42.6%) were vaccinated, but in almost 20% of DMD families, none of the family members was vaccinated. Respondents revealed anxiety related both to the vaccination procedure and to COVID-19 infection (complications after infection 93.6%, death 62.4% respondents). Changes in health care system organization also aroused concern among participants (85.3%). Conclusion: The course of the COVID-19 infection in DMD patients was mild. Not enough patients with DMD and their families are vaccinated. Education about the management of COVID-19 infections and the vaccination procedure for DMD patients is needed and expected.

Keywords: COVID-19; COVID-19 pandemic; Duchenne muscular dystrophy; SARS-CoV-2 virus; anxiety; neuromuscular disease; rare diseases; vaccination against COVID-19; vaccination against SARS-CoV-2.

MeSH terms

  • COVID-19*
  • Humans
  • Morbidity
  • Muscular Dystrophy, Duchenne*
  • Patient Reported Outcome Measures
  • SARS-CoV-2
  • Surveys and Questionnaires
  • Vaccination